. Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. J Prev Alzheimers Dis. 2023;10(2):171-177. PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

Therapeutics

  1. Aduhelm